Molecular Basis of Fragile X Syndrome: Genetic Modeling in Zebrafish

With a $52,500 grant from FRAXA Research Foundation in 2008, Dr. Robert Richards and his team from the University of Adelaide studied zebrafish models and embryo development abnormalities to search for treatment targets.

Robert Richards
$52,500 Grant
Robert Richards, PhD
Principal Investigator

Ben Tucker, PhD
FRAXA Postdoctoral Fellow (2008)

University of Adelaide
2008 FRAXA Research Grant
$52,500 over 1 Year

by Robert Richards, 6/1/2008

Fragile X syndrome exhibits several characteristic symptoms including mental retardation. The disease is caused by a specific genetic mutation. This mutation causes loss of a protein — FMRP — which is needed in the brain for normal development. In addition to mental retardation, other symptoms include craniofacial abnormalities, enhanced sensitivity to sensory stimuli and some epileptic and autistic behaviors.

Existing (mouse and fly, Drosophila) genetic models of the disease indicate that the behavioural abnormalities associated with the condition may be due to abnormal connections between neurons, related to abnormal neuron shape. The zebrafish model of fragile X syndrome is an important addition to previous models to aid in understanding the molecular basis of the disease. This is because the zebrafish embryo is transparent and develops outside the mother (enabling direct observation of development in living tissues). This model also provides a highly efficient means for drug screening (drugs can be applied directly to the fish water).

We have discovered that, in the zebrafish model of fragile X, we can recapitulate the neurite defects found in the other model organisms. The zebrafish FMRP-deficient embryos also uniquely present craniofacial defects that appear to model this symptom of the human syndrome. In the mouse model, behavioral abnormalities have been ameliorated by application of a drug (2-methyl-6-(phenylethynyl)-pyridine; MPEP). We have found that applying this drug to our zebrafish model completely rescues the abnormal neurite shape. This shows that the zebrafish embryo model can be used to screen a wider range of therapeutic agents to find potential treatments for fragile X syndrome symptoms in humans. Our research may be pivotal in understanding the molecular biology and the subsequent developmental impact of drug treatments of fragile X. Understanding a drug’s activities and limitations is critical for its use in humans to avoid undesired outcomes.

Results and other works can be found at https://www.adelaide.edu.au/directory/robert.richards

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.